Menarini group and radius health, inc. present a subgroup analysis from the elacestrant pivotal phase 3 emerald clinical trial at the 2022 american society of clinical oncology (asco) annual meeting

Subgroup analysis of patients with no prior chemotherapy in emerald: a phase 3 trial evaluating elacestrant, an investigational oral selective estrogen receptor degrader (serd), vs. investigator's choice of endocrine monotherapy for er+/her2- advanced/metastatic breast cancer (mbc) florence, italy and boston , june 6, 2022 /prnewswire/ -- the menarini group ("menarini") and radius health, inc. ("radius") (nasdaq: rdus) (collectively, the "companies") today announced the presentation at the 2022 american society of clinical oncology (asco) annual meeting of data from the emerald phase 3 clinical trial (nct03778931).
RDUS Ratings Summary
RDUS Quant Ranking